“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said
() should attract more investor interest after its capital market day, according to analysts at Jefferies.
The venture capital company, which invests in disruptive growth companies, reiterated the “buy” recommendation and set the price target at 229p.
“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said in a note on Monday.
Shares were up 1.82% to 112p in afternoon trade.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE